Breaking News Instant updates and real-time market news.

ZLAB

Zai Lab

$31.62

-0.08 (-0.25%)

, NVCR

Novocure

$86.38

-1.08 (-1.23%)

07:48
08/12/19
08/12
07:48
08/12/19
07:48

Zai Lab granted NMPA Innovative Medical Device Designation for Optune

Zai Lab Limited (ZLAB) and Novocure (NVCR) announced that the China National Medical Products Administration granted Innovative Medical Device Designation for Optune, a Tumor Treating Fields delivery system that uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth and causing affected cancer cells to die. The Innovative Device Designation allows Zai Lab to take advantage of an expedited approval procedure for Optune that offers opportunities for pre-consultation with and input from the NMPA throughout the approval process. Novocure granted Zai Lab an exclusive license for Tumor Treating Fields, including the brand name Optune, in Greater China in September 2018 and Zai Lab successfully launched the product in Hong Kong for the treatment of glioblastoma late last year. Novocure markets Optune in the United States, European Union, Japan and certain other countries for the treatment of GBM and the NovoTTF-100L System, another Tumor Treating Fields delivery system, in the U.S. for the treatment of malignant pleural mesothelioma. Tumor Treating Fields is in late stage clinical development for four solid tumor indications including non-small cell lung cancer, brain metastases, pancreatic and ovarian cancers. Tumor Treating Fields was included and recommended with Level 1 evidence as a treatment for GBM in China's Glioma Treatment Guideline published in 2018.

ZLAB

Zai Lab

$31.62

-0.08 (-0.25%)

NVCR

Novocure

$86.38

-1.08 (-1.23%)

  • 15

    Aug

  • 04

    Sep

ZLAB Zai Lab
$31.62

-0.08 (-0.25%)

01/29/19
FBCO
01/29/19
INITIATION
Target $34.7
FBCO
Outperform
Zai Lab initiated with an Outperform at Credit Suisse
Credit Suisse initiated Zai Lab with an Outperform and $34.70 price target.
02/07/19
SBSH
02/07/19
UPGRADE
SBSH
Buy
Citi double upgrades MacroGenics to Buy from Sell even after 130% stock rally
Citi analyst Yigal Nochomovitz double upgraded MacroGenics (MGNX) to Buy from Sell and raised his price target for the shares to $39 from $10. The stock closed yesterday up 130%, or $14.49, to $25.60. Following yesterday's data, the analyst raised his probability of success estimate to 70% from 50% for enoblituzumab in head and neck squamous cell carcinoma and non-small cell lung cancer. Additional Phase 1 readouts in 2019 should provide further stock momentum for MacroGenics, Nochomovitz tells investors in a research note. The analyst also sees MacroGenics as positive for Zai Lab (ZLAB). The Sophia data go a long way to validate Zai's choice of partner in MacroGenics, says the analyst.
07/05/19
MACQ
07/05/19
INITIATION
MACQ
Outperform
Zai Lab initiated with an Outperform at Macquarie
07/12/19
BOFA
07/12/19
INITIATION
Target $43
BOFA
Buy
Zai Lab initiated with a Buy at BofA/Merrill
BofA Merrill Lynch analyst Yang Huang initiated Zai Lab with a Buy rating and $43 price target, citing what he views as its strong pipeline of "potential blockbusters" and its emerging in-house discovery abilities.
NVCR Novocure
$86.38

-1.08 (-1.23%)

07/26/19
WEDB
07/26/19
DOWNGRADE
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
07/26/19
WEDB
07/26/19
DOWNGRADE
Target $80
WEDB
Neutral
Novocure downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Novocure to Neutral from Outperform, telling he believes shares are now fully valued at the current levels following its recent performance. The analyst raised his price target to $80 from $57 to reflect current positive glioblastoma adoption trends, and notes that longer-term, positive results from clinical trials in new indications could give revenues a new growth trajectory beyond the underlying core GBM franchise. Nierengarten advises investors to wait for a more attractive entry point, as risks outweigh the rewards at these levels.
07/29/19
RHCO
07/29/19
UPGRADE
Target $105
RHCO
Buy
Novocure upgraded to Buy from Hold at SunTrust
SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48.
07/29/19
07/29/19
UPGRADE
Target $105

Buy
Novocure upgraded to Buy from Hold at SunTrust
As previously reported, SunTrust analyst Gregory Gilbert upgraded Novocure to Buy from Hold and raised his price target for the shares to $105 from $48. The analyst says that he has long recognized the stock as an "under-the-radar" oncology investment story that calls for investor attention, but notes that the interest and excitement about Optune's potential in future indications is growing. Gilbert notes that his updated model now includes "probability adjusted" sales for Phase 3 indications with some areas of "potential conservatism".

TODAY'S FREE FLY STORIES

DIS

Disney

$136.70

1.51 (1.12%)

15:37
08/19/19
08/19
15:37
08/19/19
15:37
Periodicals
Former accountant told SEC Disney inflated revenue for years, MarketWatch says »

A former Walt Disney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNET

21Vianet

$7.00

0.17 (2.49%)

15:34
08/19/19
08/19
15:34
08/19/19
15:34
Options
21Vianet options imply 18.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

NGL

NGL Energy Partners

$13.35

0.53 (4.13%)

15:32
08/19/19
08/19
15:32
08/19/19
15:32
Hot Stocks
NGL Energy Partners CEO acquires 60,000 common units »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USPH

U.S. Physical Therapy

$136.10

1.54 (1.14%)

15:30
08/19/19
08/19
15:30
08/19/19
15:30
Hot Stocks
U.S. Physical Therapy director Mark Brookner sells over $404K shares of stock »

U.S. Physical Therapy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

15:25
08/19/19
08/19
15:25
08/19/19
15:25
General news
Treasury Market Summary »

Treasury Market Summary:…

SNE

Sony

$55.68

-0.04 (-0.07%)

15:19
08/19/19
08/19
15:19
08/19/19
15:19
Hot Stocks
Sony to acquire Insomniac Games, terms not disclosed »

Sony Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$56.40

0.77 (1.38%)

15:19
08/19/19
08/19
15:19
08/19/19
15:19
Options
Fabrinet options imply 11.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 21

    Aug

  • 22

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/19/19
08/19
15:17
08/19/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/19/19
08/19
15:16
08/19/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

15:08
08/19/19
08/19
15:08
08/19/19
15:08
Hot Stocks
FDA approves Nabriva's Xenleta to treat community-acquired bacterial pneumonia »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 09

    Sep

IQ

iQIYI

$18.29

1.21 (7.08%)

15:04
08/19/19
08/19
15:04
08/19/19
15:04
Options
iQiyi options imply 16.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADI

Analog Devices

$111.23

0.73 (0.66%)

15:00
08/19/19
08/19
15:00
08/19/19
15:00
Recommendations
Analog Devices analyst commentary  »

RBC says focus of Analog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BIDU

Baidu

$104.30

7.65 (7.92%)

14:49
08/19/19
08/19
14:49
08/19/19
14:49
Options
Baidu options imply 14.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 04

    Sep

AVYA

Avaya

$12.27

-0.25 (-2.00%)

14:46
08/19/19
08/19
14:46
08/19/19
14:46
Periodicals
Avaya said to get bid from Mitel, Bloomberg says »

Avaya is weighing a bid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

TXG

10x Genomics

$0.00

(0.00%)

14:46
08/19/19
08/19
14:46
08/19/19
14:46
Syndicate
10x Genomics files for IPO, to list on Nasdaq under symbol 'TXG' »

10x Genomics filed an S-1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.05

0.085 (0.95%)

14:45
08/19/19
08/19
14:45
08/19/19
14:45
Periodicals
Ford to build two new midsize EV crossovers, Automotive News reports »

Ford Motor plans to build…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

HIIQ

Health Insurance Innovations

$17.42

-0.11 (-0.63%)

14:45
08/19/19
08/19
14:45
08/19/19
14:45
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

LAZ

Lazard

$34.27

1.14 (3.44%)

14:43
08/19/19
08/19
14:43
08/19/19
14:43
Periodicals
Lazard seen as top contender for role in Saudi Aramco IPO, Bloomberg says »

Lazard's success on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.98

4.93 (13.31%)

14:39
08/19/19
08/19
14:39
08/19/19
14:39
Upgrade
Weibo rating change  »

Weibo upgraded to Buy at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

FB

Facebook

$186.22

2.8 (1.53%)

14:33
08/19/19
08/19
14:33
08/19/19
14:33
Hot Stocks
Facebook says removing 'coordinated inauthentic behavior' from China »

Facebook's Nathaniel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

GOOG

Alphabet

$1,201.56

24.62 (2.09%)

, GOOGL

Alphabet Class A

$1,203.66

24.97 (2.12%)

14:32
08/19/19
08/19
14:32
08/19/19
14:32
Periodicals
'Cyberpunk 2077' coming to Google Stadia, Verge reports »

Google (GOOG) announced…

GOOG

Alphabet

$1,201.56

24.62 (2.09%)

GOOGL

Alphabet Class A

$1,203.66

24.97 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

TRP

TC Pipeline

$48.70

0.3 (0.62%)

, SRE

Sempra Energy

$139.87

0.93 (0.67%)

14:31
08/19/19
08/19
14:31
08/19/19
14:31
Periodicals
Mexico near pact with pipeline builders, Reuters reports »

Mexico is close to…

TRP

TC Pipeline

$48.70

0.3 (0.62%)

SRE

Sempra Energy

$139.87

0.93 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$42.03

4.98 (13.44%)

14:30
08/19/19
08/19
14:30
08/19/19
14:30
Upgrade
Weibo rating change  »

Weibo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

NBRV

Nabriva Therapeutics

$2.13

-0.14 (-6.17%)

14:28
08/19/19
08/19
14:28
08/19/19
14:28
Hot Stocks
Breaking Hot Stocks news story on Nabriva Therapeutics »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 09

    Sep

LAZ

Lazard

$33.90

0.77 (2.32%)

14:24
08/19/19
08/19
14:24
08/19/19
14:24
Periodicals
Breaking Periodicals news story on Lazard »

Lazard seen as top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.